Leiblich Aaron
Nuffield Department of Surgical Sciences, John Radcliffe Hospital, University of Oxford, Headington, Oxford, UK.
Department of Urology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Headington, Oxford, UK.
Curr Urol Rep. 2017 Nov 13;18(12):100. doi: 10.1007/s11934-017-0748-x.
This review aims to evaluate research surrounding the utility of urinary biomarkers to detect bladder cancer and predict recurrence.
Recent research has focussed on the evaluation of genetic markers found in urine to provide diagnostic and prognostic information. Furthermore, the isolation and characterisation of extracellular vesicles (EVs) from the urine patients with bladder cancer provide an exciting new development in biomarker research that is set to expand in the coming years. Current urinary biomarker research is a broad field that encompasses the evaluation of urinary proteins, DNA, RNA and EVs to detect signatures that can be used to predict the presence of bladder cancer and provide prognostic information. EVs in particular offer an exciting and novel perspective in the search for accurate bladder cancer biomarkers.
本综述旨在评估围绕尿液生物标志物在检测膀胱癌及预测复发方面效用的研究。
近期研究聚焦于对尿液中发现的基因标志物进行评估,以提供诊断和预后信息。此外,从膀胱癌患者尿液中分离和鉴定细胞外囊泡(EVs)为生物标志物研究带来了令人兴奋的新进展,预计在未来几年还会进一步拓展。当前尿液生物标志物研究是一个广泛的领域,涵盖对尿蛋白、DNA、RNA和EVs的评估,以检测可用于预测膀胱癌存在并提供预后信息的特征。特别是EVs在寻找准确的膀胱癌生物标志物方面提供了一个令人兴奋的新视角。